| Document |
Document Title |
|
WO/2024/076976A1 |
The disclosure provides polypeptides and polymers, and methods of using the same for reducing the risk of, preventing, or treating inflammation.
|
|
WO/2024/077104A2 |
The present disclosure, at least in part, is based on the discovery of novel anti-Fibroblast activation protein (FAP) antibodies or antigen binding fragments thereof, and genetically modified cells (e.g., iNKT cells) expressing chimeric ...
|
|
WO/2024/074119A1 |
A recombinant collagen and the use thereof in cartilage repair matrix. The recombinant collagen comprises a sequence as shown in SEQ ID No.1; the amino acid sequence of the recombinant collagen comprises N basic repeating units, and the ...
|
|
WO/2024/074571A1 |
Nipah virus (NiV) is a recently emergent, highly pathogenic, zoonotic paramyxovirus. The inventors now designed an anti-CD40 mAb associated either with the Niv G ectodomain protein (Generation-1 vaccine), or the Niv G ectodomain protein ...
|
|
WO/2024/075767A1 |
The purpose of the present invention is to provide: a method for conveniently introducing a gene into a mitochondrion from the outside of a cell; and a method for introducing a nucleic acid having a relatively large size into a mitochond...
|
|
WO/2024/077110A2 |
The present disclosure provides isolated polynucleotides comprising sequences encoding uORF peptides and variants and fragments thereof. The present disclosure also provides constructs and vectors containing the polynucleotides. The pres...
|
|
WO/2023/044495A8 |
Type 1 diabetes (T 1 D) is caused by the autoimmune destruction of insulin producing beta cells in the islets of Langerhans leading to dependence on exogeneous insulin injections for survival. A need exists for a treatment that would pre...
|
|
WO/2024/030583A3 |
The present disclosure pertains to modified immune cells comprising one or more chimeric antigen receptors (CARs) and methods of using and making immune cells comprising one or more CARs.
|
|
WO/2024/077256A1 |
The present invention discloses methods and platforms for generating protein binding proteins with specificity for native peptide-MHC (pMHC) complexes. The pMHC binding proteins can be used in bi-specific antibodies or for generating CAR...
|
|
WO/2024/076940A1 |
Nucleic acids are described that encode for triggering receptor expressed on myeloid cells 2 (TREM2) and that can be used in expression constructs, vectors and gene therapies. Also described are methods of using the same for the treatmen...
|
|
WO/2024/077135A1 |
Provided herein are MAGEA1 immunogenic peptides, binding proteins recognizing MAGEA1 immunogenic peptides, and uses thereof.
|
|
WO/2024/047090A3 |
The present invention relates to a modified virus-like particle (VLP) of cucumber mosaic virus (CMV) comprising at least one chimeric CMV polypeptide, wherein said at least one chimeric CMV polypeptide comprises, preferably consists of (...
|
|
WO/2024/075112A1 |
Provided herein are recombinant AAT proteins having high fucosylation levels and enhanced immunomodulatory biological activity as compared to a plasma derived AAT. Further provided are compositions including the same and methods for prep...
|
|
WO/2024/044560A3 |
A novel composition and method of enhancing wound healing and minimizing rejection of an implant is presented. The composition is a dry acellular mixture comprised of conditioned media from mesenchymal stem cells, a multifunctional prote...
|
|
WO/2024/075024A1 |
This invention relates to methods for purifying type II collagen from cartilage tissue. The present invention also relates to a type II collagen composition, and the use of the type II collagen composition as a dietary supplement or trea...
|
|
WO/2024/074584A1 |
The present invention relates to stabilized pre-fusion human parainfluenza virus 3 (HPIV3) F protein, and fragments thereof. The invention also relates to nucleic acid molecules encoding such proteins and fragments, and to the use of the...
|
|
WO/2024/076577A1 |
An aqueous formulation includes a PEDF-derived short peptide (PDSP); a blend of PVP/PVA in different ratios around 8/2 – 2/8; and a tonicity agent, which is preferably non-ionic. The PDSP is preferably 14-39 amino acids long and has th...
|
|
WO/2024/075851A1 |
The purpose of the present invention is to provide a novel nucleic acid construct that induces antibody production. The present invention provides a nucleic acid construct that induces antibody production against a target protein, the nu...
|
|
WO/2024/074105A1 |
The present invention belongs to the field of biopharmaceuticals. Provided in the present invention are keratin YK93-4, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell contain...
|
|
WO/2024/077170A1 |
Provided are antibodies that specifically bind to human urokinase-type plasminogen activator receptor (uPAR). In some instances, the antibodies are cross-reactive one or more non-human animal uPAR polypeptides, such as a non-human primat...
|
|
WO/2023/173061A3 |
Neurodegeneration in Alzheimer's disease (AD) is caused by a combination of environmental and genetic factors. This disclosure relates to novel Amyloid Precursor Protein (APP) targeting sequences, novel branched oligonucleotides, and nov...
|
|
WO/2023/150771A9 |
Here we developed a COVID-19 vaccine using delta strain spike protein as the antigen to provide a more comprehensive protection against delta strain, and possibly certain degree of protection against other known variants. In combination ...
|
|
WO/2024/076190A1 |
The present invention provides a mutant of adeno-associated virus serotype 1 (AAV1) capsid protein, a nucleic acid encoding the mutant of AAV1 capsid protein, a recombinant AAV1 vector carrying the nucleic acid encoding the mutant of AAV...
|
|
WO/2024/074706A1 |
Disclosed herein are designed ankyrin repeat domain specifically binding to fibroblast activation protein (FAP). Such designed ankyrin repeat domains can be used in recombinant adapter molecules that are displayed on adenoviruses. Adenov...
|
|
WO/2024/050380A3 |
The invention provides methods of detecting a sequence modification (e.g., a genetic fusion or deletion) associated with cancer development that results in expression of a neoantigen. The neoepitope serves as the basis for manufacture of...
|
|
WO/2024/050452A3 |
It has been discovered that immunogens of conserved proteins from Gram-negative bacteria (GNB) co-administered with IL1α provoke a strong T-cell response to the bacteria from which the immunogens were derived. The compositions further p...
|
|
WO/2024/077134A1 |
Provided herein are FRAME immunogenic peptides, binding proteins recognizing FRAME immunogenic peptides, and uses thereof.
|
|
WO/2024/076499A2 |
The technology described herein is directed to stromal-free methods of T cell differentiation using a soluble Notch ligand. Also described herein are soluble Notch oligomer complexes and compositions thereof, and methods for making the s...
|
|
WO/2024/077247A1 |
The present disclosure provides compositions and methods useful in the treatment of trinucleotide repeat disorders, including Huntington's disease and Friedreich's ataxia. The present disclosure also provides gRNAs designed to target the...
|
|
WO/2023/225572A3 |
Disclosed herein, in aspects, are compositions, methods, kits, and systems relating to efficient delivery of freights (e.g., therapeutic freights) into cells, for instance, for in vivo delivery. More specifically, the delivery vehicle is...
|
|
WO/2024/040170A3 |
Spinal fusion is a surgical procedure to treat debilitating back and neck pain where two adjacent spinal vertebrae are fused by inducing bone growth between them. While iliac crest autograft bone has been the gold standard for spinal fus...
|
|
WO/2024/077191A1 |
In certain aspects, the disclosure relates to a nucleic acid molecule encoding one or more different thanotransmission polypeptides. Vectors (e.g., engineered viruses, plasmids and transposons), cells and pharmaceutical compositions comp...
|
|
WO/2023/183912A3 |
The present disclosure provides, in some aspects, an immunodeficient NOD-Fcgr1 null mouse that may be used to measure human IgG antibody pharmacokinetics and activity, produce human IgG antibodies, and model human disease treatment.
|
|
WO/2024/076136A1 |
The present invention relates to a fusion peptide complex comprising a transmembrane domain and use thereof, through which Gram-positive, Gram-negative and multidrug-resistant bacteria can be simultaneously captured in a specimen. Partic...
|
|
WO/2024/074888A2 |
Synthetic apomixis can be achieved in an F1 hybrid of rice by inducing MiMe mutations and egg cell expression of BBM1 in a single step, while simultaneously providing an increased efficiency of clonal seed production. This can be used to...
|
|
WO/2024/077151A1 |
The present disclosure provides fusion proteins comprises fusion proteins comprising the signal sequence of PduB or PduM and a heterologous protein, as well as constructs for expressing the fusion proteins, and methods of their use. The ...
|
|
WO/2024/077116A1 |
A pharmaceutical composition for use in promoting bone/cartilage regeneration, includes a PEDF-derived short peptide (PDSP); and mesenchymal stem cells (MSCs). The PDSP is 14-39 amino acids long. The PDSP has the amino-acid sequence sele...
|
|
WO/2024/026107A3 |
Novel anti-effector moiety antibodies or antigen binding domains thereof and CARs that contain such effector moiety antigen binding domains, either with or without one or more booster elements, and host cells expressing the receptors, an...
|
|
WO/2024/076121A1 |
The present invention relates to immune cells co-expressing IL-15 and a chimeric antigen receptor comprising an OX40 ligand as an intracellular signaling domain, and to a composition for preventing or treating cancer comprising same as a...
|
|
WO/2023/221936A9 |
Provided are a protein comprising a PD-L1 binding moiety linked to a TGF β binding moiety, an IL-1 binding moiety, an immunostimulating polypeptide (such as soluble LAG3 or soluble CD4) or a CD47 binding moiety, and a pharmaceutical pre...
|
|
WO/2024/050498A3 |
The present invention relates to a vesicular stomatitis virus vaccine vector encoding a MARV glycoprotein (rVSVΔG-MARV-GP). Vaccination with as little as 200 plaque-forming units was 100% efficacious against MARV lethality and prevented...
|
|
WO/2024/076375A1 |
The disclosure provides amino acid sequences (e.g., antibodies) that can bind Glypican 3 Protein (GPC3). The disclosure relates to antigen binding fragments of GPC3 antibodies, conjugates, including immunoconjugates, of GPC3 antibodies, ...
|
|
WO/2024/074142A1 |
Provided are codon-optimized GBA1polynucleotides that encode a GCase protein, with a portion of the coding sequence deviating from the wild-type. Additionally provided are expression constructs, vectors, viral particles, or compositions ...
|
|
WO/2023/215302A3 |
Methods of treating cancer in subjects in need thereof by administering a combination therapy including (a) a T cell expressing a T cell antigen coupler (TAC) polypeptide having (i) an antigen-binding domain that binds a target antigen, ...
|
|
WO/2024/073848A1 |
The present disclosure relates to pharmaceutical compositions and methods for the preparation, manufacture and therapeutic use of nucleic acid vaccines comprising lipid nanoparticles (LNP) wherein the LNPs comprise cationic lipids, non-c...
|
|
WO/2024/076237A1 |
The invention relates to a protein comprising at least one ice-binding alpha helix, wherein the ice-binding helix has a twist of less than 100 degrees per residue, preferably a twist of less than 99 degrees per residue, most preferably a...
|
|
WO/2024/077251A2 |
Disclosed are de novo designed polypeptide agonists and antagonists of IL-21, conditionally-active IL-21 agonists and antagonists, and methods for using them to treat cancer or to modulate an immune response.
|
|
WO/2024/074634A1 |
The present disclosure provides RNA technologies for targeting Claudin-18.2 polypeptides. In some embodiments, such RNA technologies can be useful for treatment of diseases associated with positive expression of Claudin-18.2. For example...
|
|
WO/2024/076960A2 |
A vaccine formulation for humans or other mammals (including dogs, horses, and cats) is provided. The vaccine formulation includes two chimeric proteins designed to elicit antibodies that bind to several targets on the surface of Lyme di...
|
|
WO/2024/074713A1 |
The present invention relates to the adoptive therapy using notably CAR-T cells. Here the inventors used a lentiviral vector approach to silence RINF expression in a shRNA- dependent manner and evaluate the consequences of RINF silencing...
|
